safe
stabl
blood
suppli
paramount
function
health
system
regulatori
agenc
blood
provid
medic
profession
continu
implement
improv
measur
guarante
safe
blood
suppli
much
effort
initi
face
emerg
infecti
threat
blood
suppli
exemplifi
experi
hiv
despit
implement
hiv
blood
screen
test
one
success
reactiv
safeti
measur
ever
implement
societi
still
pay
high
price
term
human
live
health
result
prepar
emerg
pandem
aid
experi
emphas
fact
although
zero
risk
blood
transfus
unattain
provis
safest
blood
possibl
must
remain
one
biggest
commit
world
polici
modern
time
character
intens
world
travel
migrat
increas
global
commerci
interdepend
global
factor
add
demograph
chang
contribut
complex
task
maintain
safe
blood
spain
pioneer
use
pathogen
reduct
technolog
prt
initi
treatment
fresh
frozen
plasma
ffp
applic
proactiv
risk
reduct
measur
meant
contain
dissemin
infecti
diseas
time
continu
threat
seen
recent
exampl
hivaid
sever
acut
respiratori
syndrom
sar
chikungunya
dengu
outbreak
well
west
nile
viru
infect
blood
transfus
center
galicia
suppli
blood
hospit
popul
million
inhabit
northwestern
region
spain
collect
approxim
whole
blood
apheresi
donat
per
year
sinc
riboflavinbas
pathogen
reduct
pathogen
reduct
clinic
perform
summari
introduct
studi
assess
feasibl
perform
safeti
mirasol
treat
platelet
concentr
mpc
store
day
method
prospect
observ
studi
approv
ethic
committe
univers
clinic
santiago
de
compostela
inform
consent
ask
patient
receiv
mpc
mpc
treat
mirasol
system
accord
manufactur
instruct
thrombocytopen
patient
transfus
accord
spanish
transfus
guidelin
posttransfus
platelet
count
measur
h
andor
h
transfus
posttransfus
surveil
patient
maintain
studi
result
data
evalu
patient
transfus
analyz
mean
age
patient
year
mean
age
mpc
transfus
day
mean
platelet
dose
transfus
respons
measur
mean
correct
count
increment
h
transfus
cci
cci
respect
transfus
result
cci
valu
transfus
result
cci
valu
conclus
use
mpc
support
treatment
prove
safe
effect
cohort
thrombocytopen
patient
recent
blood
transfus
center
galicia
assess
qualiti
mirasol
prttreat
terumo
bct
lakewood
co
usa
platelet
concentr
mpc
store
plateletaddit
solut
day
technolog
use
riboflavin
vitamin
b
uv
light
reduc
pathogen
load
inactiv
contamin
white
blood
cell
blood
compon
result
studi
demonstr
accept
platelet
qualiti
prompt
blood
transfus
center
univers
clinic
santiago
de
compostela
start
clinic
studi
investig
perform
product
support
therapi
thrombocytopen
patient
studi
design
assess
feasibl
perform
safeti
mpc
store
day
protocol
prospect
observ
studi
submit
ethic
committe
univers
clinic
santiago
de
compostela
grant
approv
start
studi
patient
receiv
mpc
sign
inform
consent
form
start
therapi
platelet
concentr
process
whole
blood
collect
orbisac
technolog
terumo
bct
treat
mirasol
prt
system
accord
manufactur
instruct
use
treatment
mpc
immedi
releas
addit
treatment
platelet
solv
plateletaddit
solut
ssp
macopharma
origin
buffi
coat
pool
store
day
c
agit
blood
process
treatment
done
accord
protocol
describ
earlier
public
exclus
stabl
thrombocytopen
patient
enrol
studi
patient
maintain
prophylact
plateletsupport
therapi
accord
spanish
intern
transfus
guidelin
well
accord
institut
standard
practic
patient
age
receiv
least
u
mpc
includ
studi
patient
exclud
refractori
platelet
transfus
show
activ
bleed
transfus
need
surgeri
inform
consent
form
sign
patient
receiv
aborh
groupcompat
platelet
posttransfus
platelet
count
measur
h
andor
h
transfus
furthermor
posttransfus
surveil
patient
maintain
studi
period
statist
analys
conduct
use
sasbas
sasstat
softwar
version
sa
system
window
sa
institut
inc
cari
nc
usa
cell
counter
three
depart
use
sysmex
sysmex
norderstedt
germani
blood
transfus
center
coulter
act
posttransfus
platelet
count
measur
h
andor
h
transfus
ci
count
increment
cci
correct
count
increment
calcul
use
follow
formula
bsa
bodi
surfac
area
ci
posttransfus
platelet
count
pretransfus
platelet
count
ci
posttransfus
platelet
count
pretransfus
platelet
count
cci
ci
transfus
platelet
dose
bsa
cci
ci
transfus
platelet
dose
bsa
bsa
height
weight
mean
yield
transfus
mpc
rang
standard
deviat
sd
mean
age
mpc
time
transfus
day
rang
day
sd
day
nearli
platelet
transfus
day
remain
transfus
day
patient
patient
enrol
initi
one
patient
exclud
due
refractori
total
transfus
data
patient
transfus
analyz
mean
age
patient
year
rang
year
patient
male
tabl
show
patient
group
diagnosi
acut
leukemia
includ
acut
lymphoblast
leukemia
acut
myeloid
leukemia
aml
nonhodgkin
lymphoma
nhl
includ
bcell
lymphoma
hodgkin
lymphoma
hl
myelodysplast
syndrom
md
marrow
aplasia
includ
aplasia
hypoplasia
nonhematolog
diseas
includ
postcardiac
surgeri
liver
cirrhosi
clinic
factor
led
increas
platelet
consumpt
absent
enrol
patient
suscept
patient
show
symptom
fever
andor
infect
recent
undergon
bone
marrow
transplant
data
measur
ident
sampl
three
differ
cell
counter
appear
normal
distribut
shapirowilk
p
demonstr
figur
three
popul
measur
three
counter
found
normal
distribut
shapirowilk
p
anova
reveal
differ
counter
p
descript
statist
variabl
plot
box
plot
show
similar
popul
distribut
counter
henc
data
collect
counter
could
use
without
calibr
extrapol
mean
number
transfus
per
patient
rang
sd
median
consid
togeth
observ
mean
transfus
cci
n
cci
n
tabl
transfus
show
cci
level
intern
accept
threshold
success
transfus
cci
cci
fig
base
mean
valu
cci
transfus
respons
lower
threshold
patient
acut
leukemia
cci
hl
cci
fig
two
acut
transfus
reaction
grade
imput
consid
possibl
observ
transfus
mirasol
prt
technolog
partial
implement
blood
transfus
center
galicia
guarante
continu
suppli
mpc
depart
hematolog
hemotherapi
univers
clinic
santiago
de
compostela
studi
period
due
simplic
educ
oper
implement
technolog
went
smoothli
treat
product
releas
earlier
one
treat
altern
technolog
employ
site
sinc
studi
clinic
perform
mpc
evalu
postcount
increment
determin
prophylact
transfus
thrombocytopen
patient
previou
studi
could
show
clear
relationship
transfus
failur
defin
increment
intern
recogn
threshold
bleed
complic
studi
design
chosen
enabl
perform
close
possibl
routin
process
hospit
also
allow
compar
analysi
routin
experi
report
literatur
thu
prospect
studi
count
increment
level
use
marker
clinic
perform
cci
marker
platelet
recoveri
use
surrog
platelet
qualiti
henc
result
show
rate
effect
transfus
multipl
transfus
patient
lie
definit
within
expect
level
respons
confirm
adequ
platelet
qualiti
level
success
transfus
slightli
inferior
report
investig
netherland
equal
recent
observ
switzerland
superior
report
norway
instanc
platelet
treat
altern
pathogen
reduct
technolog
use
moreov
observ
rate
slightli
inferior
observ
miracl
studi
transfus
mpc
cci
marker
surviv
consequ
depend
patient
condit
view
fact
patient
present
platelet
consumpt
factor
time
transfus
success
respons
rate
quit
accept
patient
variabl
becom
evid
clinic
respons
patient
group
analyz
fig
besid
respons
rate
observ
present
studi
rang
observ
studi
use
altern
technolog
rang
dutch
norwegian
swiss
report
miracl
studi
respons
cci
threshold
observ
transfus
regard
safeti
two
mild
allerg
reaction
record
patient
resolv
without
medic
reaction
consid
possibl
relat
transfus
blood
product
impli
rate
advers
event
relat
transfus
rate
far
observ
rate
report
elsewher
pathogeninactiv
platelet
product
treat
altern
technolog
consist
prior
report
mpt
altogeth
experi
acquir
process
mpt
routinelik
condit
use
support
treatment
thrombocytopen
patient
show
technolog
easi
implement
blood
bank
routin
treat
plateletcontain
product
safe
effect
